Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.


Off-target binding can significantly affect the pharmacokinetics (PK), tissue distribution, efficacy and toxicity of a therapeutic antibody. Herein we describe the development of a humanized anti- fibroblast growth factor receptor 4 (FGFR4) antibody as a potential therapeutic for hepatocellular carcinoma (HCC). A chimeric anti FGFR4 monoclonal antibody… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.